HighTower Advisors
GANX icon

HighTower Advisors’s Gain Therapeutics GANX Stock Holding History

HighTower Advisors’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9K Buy
+17,174
New +$31.7K ﹤0.01% 3745
2025
Q4 		– Sell
-11,574
Closed -$20.5K – 3768
2025
Q3 		$20.5K Buy
+11,574
New +$19.5K ﹤0.01% 3671

Other funds holding GANX

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BFA
Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HighTower Advisors's GANX Position: Q2 2026 in Review

HighTower Advisors opened a new position in Gain Therapeutics (GANX) in Q2 2026: 17,174 shares worth $34.9K. The stake represents ﹤0.01% of the portfolio and ranks #3745 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in GANX as recently as Q3 2025.

HighTower Advisors first reported a position in GANX in Q3 2025 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • HighTower Advisors held 17,174 shares of Gain Therapeutics worth $34.9K as of Q2 2026.
  • Gain Therapeutics was a new HighTower Advisors position in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3745 holding.
  • HighTower Advisors first reported a position in Gain Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.